title: Vitamin D and nifedipine in the treatment of Chinese patients with grades I-II essential hypertension: a randomized placebo-controlled trial.
abstract: Low vitamin D status has been shown to be associated with hypertension. We planned to research the effect of vitamin D and nifedipine in the treatment of patients with essential hypertension.
  
  
  
  Patients with grades I-II essential hypertension were enrolled in this single-center, double-blind, placebo-controlled trial in Beijing. All patients received a conventional antihypertensive drug (nifedipine, 30 mg/d). One hundred and twenty-six patients were randomly assigned to receive vitamin D (n=63, 2000 IU/d) or a placebo (n=63) as an add-on to nifedipine, by the method of permutated block randomization. Ambulatory blood pressure monitoring was performed at baseline (month 0), at month 3 and at month 6.
  
  
  
  In vitamin D supplementation group, there was a significant increase in mean 25-hydroxyvitamin D levels from baseline (19.4 ± 11.6 ng/ml) to 6 months (34.1 ± 12.2 ng/ml; p<0.001). At 6 months, the primary end points, a difference in the fall of 24-h mean blood pressure, between the groups was -6.2 mmHg (95% CI -11.2; -1.1) for systolic blood pressure (p<0.001) and -4.2 mmHg (95% CI -8.8; -0.3) for diastolic blood pressure (p<0.001) under intention to treat analysis. In patients with vitamin D <30 ng/ml at baseline (n=113), 24-h mean blood pressure decreased by 7.1/5.7 mmHg (p<0.001). Safety and tolerability were similar among the two groups.
  
  
  
  Vitamin D supplementation can reduce blood pressure in patients with hypertension, it can be an adjuvant therapy for patients with grades I-II essential hypertension.
  
  
  
  This study was registered in the Chinese Clinical Trial Registry, it is available in Website: http://www.chictr.org/cn/;
  
  
  
  ChiCTR-ONC-13003840.
authors.affiliation: Department of South-Building Cardiology, PLA General Hospital at Beijing, Beijing 100853, China.
authors.forename: Wei Ren
authors.initials: WR
authors.lastname: Chen
authors.affiliation: Department of South-Building Cardiology, PLA General Hospital at Beijing, Beijing 100853, China.
authors.forename: Zhi Ying
authors.initials: ZY
authors.lastname: Liu
authors.affiliation: Department of South-Building Cardiology, PLA General Hospital at Beijing, Beijing 100853, China. Electronic address: chen_weiren@sina.com.
authors.forename: Yang
authors.initials: Y
authors.lastname: Shi
authors.affiliation: Department of South-Building Cardiology, PLA General Hospital at Beijing, Beijing 100853, China.
authors.forename: Da Wei
authors.initials: DW
authors.lastname: Yin
authors.affiliation: Department of South-Building Cardiology, PLA General Hospital at Beijing, Beijing 100853, China.
authors.forename: Hao
authors.initials: H
authors.lastname: Wang
authors.affiliation: Department of South-Building Cardiology, PLA General Hospital at Beijing, Beijing 100853, China.
authors.forename: Yuan
authors.initials: Y
authors.lastname: Sha
authors.affiliation: Department of Cardiology, PLA General Hospital at Beijing, Beijing 100853, China.
authors.forename: Yun Dai
authors.initials: YD
authors.lastname: Chen
mesh_terms: D000368:Aged; D001794:Blood Pressure; D002097:C-Reactive Protein / Q000378:metabolism; D002681:China; D019587:Dietary Supplements; D004311:Double-Blind Method; D000075222:Essential Hypertension; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009543:Nifedipine / Q000008:administration & dosage / Q000627:therapeutic use*; D015203:Reproducibility of Results; D016896:Treatment Outcome; D014807:Vitamin D / Q000627:therapeutic use*
chemical_list: D014807:Vitamin D; D002097:C-Reactive Protein; D009543:Nifedipine
keywords: Adjuvant therapy; Hypertension; Supplementation; Vitamin D